NASDAQ:CHRS - Coherus BioSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.83
  • Forecasted Upside: 69.63 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.64
▼ -0.43 (-2.85%)

This chart shows the closing price for CHRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coherus BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRS

Analyst Price Target is $24.83
▲ +69.63% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Coherus BioSciences in the last 3 months. The average price target is $24.83, with a high forecast of $30.00 and a low forecast of $20.00. The average price target represents a 69.63% upside from the last price of $14.64.

This chart shows the closing price for CHRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Coherus BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021BarclaysLower Price TargetOverweight$28.00 ➝ $24.00High
5/13/2021HC WainwrightLower Price TargetBuy$29.00 ➝ $26.00Low
5/7/2021Maxim GroupInitiated CoverageBuy$22.00Low
5/7/2021HC WainwrightLower Price TargetBuy$28.00 ➝ $26.00High
2/25/2021CitigroupLower Price Target$30.00 ➝ $27.00High
2/25/2021HC WainwrightLower Price TargetBuy$33.00 ➝ $29.00High
11/19/2020MizuhoLower Price TargetBuy$35.00 ➝ $30.00Low
11/6/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $32.00High
8/7/2020Maxim GroupInitiated CoverageBuy$27.00High
8/7/2020HC WainwrightBoost Price TargetBuy$30.00 ➝ $33.00Medium
7/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
5/9/2020Maxim GroupInitiated CoverageBuy$27.00Medium
5/8/2020HC WainwrightReiterated RatingBuy$30.00High
4/17/2020SunTrust BanksInitiated CoverageBuy$26.00High
3/5/2020Credit Suisse GroupReiterated RatingBuy$36.00Low
2/29/2020Maxim GroupReiterated RatingBuy$27.00High
2/28/2020HC WainwrightBoost Price TargetBuy$29.00 ➝ $30.00High
2/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$33.00 ➝ $35.00Medium
2/4/2020MizuhoReiterated RatingBuy$43.00High
11/27/2019MizuhoInitiated CoverageBuy$43.00Medium
11/25/2019HC WainwrightReiterated RatingBuy$29.00Low
11/8/2019Credit Suisse GroupReiterated RatingBuy$36.00Low
9/29/2019MizuhoSet Price TargetBuy$43.00Medium
8/13/2019MizuhoInitiated CoverageBuy ➝ Buy$43.00Medium
8/12/2019BarclaysSet Price TargetBuy$31.00Low
8/2/2019Maxim GroupReiterated RatingBuy ➝ Buy$25.00 ➝ $27.00High
8/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $29.00High
7/10/2019Maxim GroupReiterated RatingBuy$25.00Low
6/21/2019BarclaysSet Price TargetBuy$30.00Low
6/19/2019Robert W. BairdSet Price TargetBuy$28.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$30.00Medium
5/10/2019Maxim GroupSet Price TargetBuy$25.00High
5/7/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
4/10/2019Robert W. BairdSet Price TargetBuy$28.00Low
4/8/2019Maxim GroupReiterated RatingBuy$25.00High
3/7/2019Credit Suisse GroupSet Price TargetBuy$25.00Medium
11/5/2018HC WainwrightSet Price TargetBuy$28.00High
11/2/2018CowenReiterated RatingBuy$45.00High
9/26/2018HC WainwrightSet Price TargetBuy$28.00High
9/25/2018Maxim GroupReiterated RatingBuy$25.00Medium
8/28/2018HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$18.00 ➝ $22.00High
5/3/2018Maxim GroupSet Price TargetBuy$18.00Medium
3/9/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00Low
3/9/2018Maxim GroupReiterated RatingBuy ➝ Buy$20.00 ➝ $15.00High
11/7/2017CitigroupReiterated RatingBuy$23.00N/A
9/27/2017Credit Suisse GroupReiterated RatingOutperform$24.00 ➝ $17.00Low
9/8/2017CowenReiterated RatingOutperform$45.00Low
9/8/2017Maxim GroupReiterated RatingBuy$40.00 ➝ $20.00High
8/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$32.00 ➝ $25.00Low
6/14/2017Credit Suisse GroupReiterated RatingOutperform$38.00 ➝ $24.00Low
6/13/2017CitigroupLower Price TargetBuy$38.00 ➝ $33.00Medium
6/13/2017CowenReiterated RatingOutperform$45.00High
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 ➝ $43.00High
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 ➝ $37.00High
6/12/2017Credit Suisse GroupSet Price TargetBuy$38.00Low
6/12/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
6/12/2017Maxim GroupLower Price TargetBuy ➝ Buy$44.00 ➝ $40.00Medium
5/21/2017BarclaysReiterated RatingOverweight$46.00High
5/17/2017CitigroupSet Price TargetBuy$38.00High
5/15/2017BMO Capital MarketsReiterated RatingOutperform$54.00N/A
5/15/2017Maxim GroupSet Price TargetBuy$43.00Medium
5/9/2017Maxim GroupSet Price TargetBuy$43.00High
5/5/2017BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$54.00Medium
4/21/2017Credit Suisse GroupReiterated RatingBuy$38.00High
3/16/2017Credit Suisse GroupReiterated RatingBuy$38.00High
3/14/2017Maxim GroupReiterated RatingBuy$43.00Medium
2/1/2017Robert W. BairdReiterated RatingOutperform$40.00N/A
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/A
11/10/2016Maxim GroupReiterated RatingBuyN/A
11/7/2016CitigroupReiterated RatingBuy$36.00N/A
10/18/2016Robert W. BairdInitiated CoverageOutperform$40.00N/A
10/8/2016Maxim GroupSet Price TargetBuy$43.00N/A
10/4/2016BarclaysReiterated RatingOverweight$46.00N/A
9/28/2016Credit Suisse GroupReiterated RatingBuy$38.00N/A
9/17/2016Credit Suisse GroupSet Price TargetBuy$38.00N/A
9/7/2016Maxim GroupInitiated CoverageBuy$43.00N/A
8/11/2016BarclaysReiterated RatingBuy$46.00N/A
7/27/2016CitigroupInitiated CoverageBuy$36.00N/A
(Data available from 6/23/2016 forward)
Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $14.64
Low: $14.48
High: $15.22

50 Day Range

MA: $14.09
Low: $12.95
High: $15.26

52 Week Range

Now: $14.64
Low: $12.90
High: $22.22

Volume

786,414 shs

Average Volume

1,138,530 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Coherus BioSciences?

The following equities research analysts have issued research reports on Coherus BioSciences in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., HC Wainwright, Maxim Group, Mizuho, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CHRS.

What is the current price target for Coherus BioSciences?

6 Wall Street analysts have set twelve-month price targets for Coherus BioSciences in the last year. Their average twelve-month price target is $24.83, suggesting a possible upside of 68.8%. Mizuho has the highest price target set, predicting CHRS will reach $30.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $20.00 for Coherus BioSciences in the next year.
View the latest price targets for CHRS.

What is the current consensus analyst rating for Coherus BioSciences?

Coherus BioSciences currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHRS will outperform the market and that investors should add to their positions of Coherus BioSciences.
View the latest ratings for CHRS.

What other companies compete with Coherus BioSciences?

How do I contact Coherus BioSciences' investor relations team?

Coherus BioSciences' physical mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company's listed phone number is 650-649-3530 and its investor relations email address is [email protected] The official website for Coherus BioSciences is www.coherus.com.